Shenmai injection added to standard medical treatment for heart failure improved cardiac function (P<0.05) and energy metabolism compared to trimetazidine or standard treatment alone.
RCT (n=120)
Single-blind
randomized
Does Shenmai injection improve energy metabolism and cardiac function in patients with heart failure?
Shenmai injection added to standard medical therapy for 7 days may improve energy metabolism and cardiac function in patients with heart failure compared to standard therapy alone or trimetazidine.
BACKGROUND: In recent years, the application of Shenmai (SM) injection, a traditional Chinese medicine (TCM), to treat heart failure (HF) has been gradually accepted in China. However, whether SM improves energy metabolism in patients with HF has not been determined due to the lack of high-quality studies. We aimed to investigate the influence of SM on energy metabolism in patients with HF. METHODS: This single-blind, controlled study randomly assigned 120 eligible patients equally into three groups receiving SM, trimetazidine (TMZ), or control in addition to standard medical treatment for HF for 7 days. The primary endpoints were changes in free fatty acids (FFAs), glucose, lactic acid (LA), pyroracemic acid (pyruvate, PA) and branched chain amino acids (BCAAs) in serum. The secondary outcomes included the New York Heart Association (NYHA) functional classification, TCM syndrome score (TCM-s), left ventricular injection fraction (LVEF), left ventricular internal diastolic diameter (LVIDd), left ventricular internal dimension systole (LVIDs), and B-type natriuretic peptide (BNP). RESULTS: After treatment for 1 week, the NYHA functional classification, TCM-s, and BNP level gradually decreased in the patients in all three groups, but these metrics were significantly increased in the patients in the SM group compared with those in the patients in the TMZ and control groups (P < 0.05). Moreover, energy metabolism was improved in the NYHA III-IV patients in the SM group compared with those in the patients in the TMZ and control groups as evidenced by changes in the serum levels of FFA, LA, PA, and BCAA. CONCLUSIONS: Integrative treatment with SM in addition to standard medical treatment for HF was associated with improved cardiac function compared to standard medical treatment alone. The benefit of SM in HF may be related to an improvement in energy metabolism, which seems to be more remarkable than that following treatment with TMZ.
Shao-mei et al. (Fri,) conducted a rct in heart failure (n=120). Shenmai (SM) injection vs. Trimetazidine (TMZ) or control (standard medical treatment) was evaluated on Changes in free fatty acids (FFAs), glucose, lactic acid (LA), pyroracemic acid (pyruvate, PA) and branched chain amino acids (BCAAs) in serum. Shenmai injection added to standard medical treatment for heart failure improved cardiac function (P<0.05) and energy metabolism compared to trimetazidine or standard treatment alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: